Send to

Choose Destination
J Med Chem. 1999 Sep 9;42(18):3557-71.

Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa.

Author information

Departments of Cardiovascular Drug Discovery and New Leads Generation, Rhône-Poulenc Rorer, 500 Arcola Road, Collegeville, Pennsylvania 19426-0107, USA.


The discovery of a series of non-peptide factor Xa (FXa) inhibitors incorporating 3-(S)-amino-2-pyrrolidinone as a central template is described. After identifying compound 4, improvements in in vitro potency involved modifications of the liphophilic group and optimizing the angle of presentation of the amidine group to the S1 pocket of FXa. These studies ultimately led to compound RPR120844, a potent inhibitor of FXa (K(i) = 7 nM) which shows selectivity for FXa over trypsin, thrombin, and several fibrinolytic serine proteinases. RPR120844 is an effective anticoagulant in both the rat model of FeCl(2)-induced carotid artery thrombosis and the rabbit model of jugular vein thrombus formation.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for American Chemical Society
Loading ...
Support Center